NASDAQ : ATHA

Athira Pharma, Inc.

$6.75 USD

-$0.44 (-6.12%)

Volume
70.31K
Average Volume
1.06M
Market Capitalization
$26.62M
P/E Ratio
-0.26
Dividend Yield
0.00%
Price Target
$4.00
Year High
$8.36
Year Low
$2.20
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$10.38
Company Overview

NASDAQ

Mark J. Litton

Biotechnology

Healthcare

ATHA

26

US

USD

425 620 8501

04746L203

0001620463

Liquidity Metrics

0.01

10.38

10.38

4.93

0.00

Sales & Valuation

-$

0.00

0.67

-0.58

-12.15

Profitability

-$24.7

-$105.61M

0.00%

0.00%

-381.01%

-180.77%

P/E Metrics

-0.26

0.00

0.00

Analyst Price Target & Rating

$4.00

$33.00

$3.00

N/A

0/5

5 Analysts

68.75%

Financial Health Scores

-9.26

2/9

$62.54M

$71.59M

$22.29M

-$8.07M

Key Metrics (TTM)

-$1.85M

0.00

0.04

10.38

-381.01%

-169.53%

-394.10%

-171.56%

-9 days

Company Executives
Name Title
Mark F. Worthington General Counsel, Chief Compliance Officer & Corporate Secretary
Kevin Church Chief Scientific Officer
Robert Renninger Chief Financial Officer
Julie Rathbun Head of Investor Relations
Mark J. Litton President, Chief Executive Officer & Director
Javier San Martin Chief Medical Officer
Poll Results

No votes yet today — be the first to share your view!

About Athira Pharma, Inc. (NASDAQ:ATHA) Stock

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric ... disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.

Athena Gold Appoints Farid Mammadov as Vice President, Investor Relations

2026-08-06 07:00:00

Toronto, Ontario--(Newsfile Corp. - August 6, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to announce the appointment of Mr. Farid Mammadov, CPIR, as Vice President, Investor Relations of the Company, effective immediately.

ATHA Energy Announces Election to Issue Common Shares in Satisfaction of US$25 Million Convertible Debenture Interest Payment Obligations

2026-07-31 07:00:00

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / July 31, 2026 / ATHA Energy Corp. ("ATHA" or the "Company") (TSXV:SASK)(OTCQX:SASKF)(FRA:X5U) announces that in accordance with the terms of the US$25,000,000 twelve percent convertible debenture issued to Queen's Road Capital Investment Ltd. ("QRC") on February 5, 2026 (the "Convertible Debenture"), the Company has elected to issue 340,136 common shares in the capital of the Company ("Common Shares") at a deemed price of US$0.735 (C$1.031) to QRC as payment for US$249,999.96 (C$350,349.941) in interest owing on the Convertible Debenture.

Athena Gold Significantly Expands Forester Project near Musselwhite, Ontario

2026-07-23 07:00:00

Toronto, Ontario--(Newsfile Corp. - July 23, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to announce that it has acquired, through map staking, an additional 3,939 hectares contiguous to its 100%-owned Forester project in Ontario's Musselwhite Gold Camp. The new claims expand the project by more than 80% to a total of 8,843 hectares.

ATHA Energy Announces Corporate Activities Update

2026-07-13 15:35:00

VANCOUVER, BC / ACCESS Newswire / July 13, 2026 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQX:SASKF) ("ATHA" or the "Company") announces the grant of an aggregate of 2,850,000 incentive stock options ("Options") and 2,200,000 restricted share units ("RSUs") to certain eligible participants, including certain directors and officers of the Company, under the Company's equity incentive plan (the "Plan"). One-third of the Options shall vest on the date of issuance thereof, one-third of the Options shall vest on the six-month anniversary of the date of issuance thereof, and the remaining one-third of the Options shall vest on the twelve-month anniversary of the date of issuance thereof.

ATHA Energy Reports Widest Intersection to Date at Rib North Discovery with 37 m of Composite Uranium Mineralization in Ribn-DD-003 – Multiple Drillholes Demonstrating Continuity of Uranium Mineralization

2026-07-09 07:00:00

HIGHLIGHTS First eight diamond drillholes completed at the RIB North Discovery (Figure 1) - as part of the recently commenced 2026 Angilak Exploration Program - outline continuity of mineralization at the primary RIB North area, along strike from the maiden discovery hole, RIBN-DD-001, over 300 m. Additionally, the Company has discovered a secondary, east-west mineralized structure along the western limb of the Mineralized RIB Corridor ("MRC") approximately 1 km from the main RIB North Discovery Area (Figure 2); Drilling is focused on widely spaced step-outs, designed to outline the continuity of uranium mineralization at RIB North - the discovery remains open in all directions; Six of the eight drillholes intersected uranium mineralization, results are highlighted by: Drillhole RIBN-DD-003: Successfully targeted uranium mineralization ~120 m along strike to the Northwest from RIBN-DD-001, resulting in the intersection of 37.0 m of total composite uranium mineralization2 over fifteen zones from 541.7 m to 652.0 m (Figure 3).

ATHA Energy Makes Major New High-Grade Discovery along the Lac 50 Corridor - Intersects 11.5 m of Composite Uranium Mineralization Including 1.6 m of Near Continuous High-Grade 4 km Along Strike from Lac 50 Deposit Area

2026-07-08 07:00:00

HIGHLIGHTS First regional test along the Lac 50 Deposit Corridor, as part of the recently commenced 2026 Angilak Exploration Program, results in major new discovery at Lac 50 Northwest, located ~4 km along strike from the Lac 50 Deposit area (Figure 1); The second hole at Lac 50 Northwest Discovery, L50W-DD-002, intersected 11.5 m of total composite uranium mineralization2 over five zones from 305.0 m to 479.9 m (Figure 2 & Table 1). The hole intersected 7.0 m of continuous mineralization (from 415.6 m to 422.6 m) averaging 7,974 counts per second (CPS1) including 1.6 m of high-grade mineralization2 with maximum radioactivity of 40,162 CPS1; Mineralization is basement-style, hosted within brecciated basalts, infilled with quartz-carbonite veining, displaying albite-hematite alteration halos and silicification overprinting.

OTC Markets Group Welcomes ATHA Energy Corp. to OTCQX

2026-06-30 07:00:00

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced ATHA Energy Corp. (TSX-V: SASK; OTCQX: SASKF and FRA: X5U), a uranium mineral exploration company, has qualified to trade on the OTCQX® Best Market. ATHA Energy Corp. upgraded to OTCQX from the OTCQB® Venture Market.

Athena Gold Provides Exploration Update from Excelsior Springs, Nevada

2026-06-16 07:00:00

White Rock, British Columbia--(Newsfile Corp. - June 16, 2026) - Athena Gold Corporation (CSE: ATHA) (OTCQB: AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project ("Excelsior" or the "Project") in Nevada. Mammoth Minerals Limited (ASX: M79) ("Mammoth") has been aggressively exploring Excelsior pursuant to its option agreement to earn an 80% interest in the Project over five years, providing Athena a free-carry to Definitive Feasibility Study thereafter (see Company press releases dated June 2, 2025, and August 22, 2025).

Frequently Asked Questions

What is the current Athira Pharma, Inc. (ATHA) stock price?

Athira Pharma, Inc.(NASDAQ:ATHA) stock price is $6.75 in the last trading session. During the trading session, ATHA stock reached the peak price of $8.36 while $2.1955 was the lowest point it dropped to. The percentage change in ATHA stock occurred in the recent session was --6.12% while the dollar amount for the price change in ATHA stock was -$0.44.

ATHA's industry and sector of operation?

The NASDAQ listed ATHA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ATHA?

Mark F. Worthington | General Counsel, Chief Compliance Officer & Corporate Secretary
Kevin Church | Chief Scientific Officer
Robert Renninger | Chief Financial Officer
Julie Rathbun | Head of Investor Relations
Mark J. Litton | President, Chief Executive Officer & Director

How many employees does ATHA have?

Number of ATHA employees currently stands at 26. ATHA operates from 18706 North Creek Parkway, Bothell, WA 98011, US.

Link for ATHA official website?

Official Website of ATHA is: https://leonabio.com

How do I contact ATHA?

ATHA could be contacted at phone #425 620 8501 and can also be accessed through its website. ATHA operates from 18706 North Creek Parkway, Bothell, WA 98011, US.

How many shares of ATHA are traded daily?

The average number of ATHA shares traded daily for last 3 months was 1.06M.

What is the market cap of ATHA currently?

The market value of ATHA currently stands at $26.62M with its latest stock price at $6.75